Old Web
English
Sign In
Acemap
>
authorDetail
>
Laurie Millar
Laurie Millar
Hoffmann-La Roche
Medicine
Placebo
Clinical trial
Psychiatry
Crenezumab
4
Papers
110
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Baseline Characteristics from a Phase III Trial of Crenezumab in Early (Prodromal-to-Mild) Alzheimer’s Disease (CREAD) (P4.1-002)
2019
Neurology
Kaycee M. Sink
Susanne Ostrowitzki
Laurie Millar
Francis Warren
Helen Lin
Jillian Smith
Andres Schneider
Reina N. Fuji
Angelica Quartino
Howard Mackey
Michael Rabbia
Susan Yule
Paulo Fontoura
Rachelle Doody
Show All
Source
Cite
Save
Citations (0)
BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER’S DISEASE (CREAD)
2018
Alzheimers & Dementia
Helen Lin
Susanne Ostrowitzki
Kaycee M. Sink
Laurie Millar
Francis Warren
Jillian Smith
Andres Schneider
Reina N. Fuji
Angelica Quartino
Howard Mackey
Michael Rabbia
Susan Yule
Paulo Fontoura
Rachelle Doody
Show All
Source
Cite
Save
Citations (1)
Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme
2016
The Lancet Psychiatry
Dragana Bugarski-Kirola
Nakao Iwata
Snjezana Sameljak
Carol Reid
Thomas Blaettler
Laurie Millar
Tiago Reis-Marques
George Garibaldi
Shitij Kapur
Show All
Source
Cite
Save
Citations (41)
Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program.
2014
PLOS ONE
Paul Emery
William F. C. Rigby
Paul P. Tak
Thomas Dörner
Ewa Olech
Carmen Martin
Laurie Millar
Helen Travers
Elena Fisheleva
Show All
Source
Cite
Save
Citations (68)
1